ANAB AnaptysBio Corp: רווח למניה בשנים עשר החודשים האחרונים

AnaptysBio, Inc. (ANAB) focuses on developing antibodies to combat inflammation, monetizing its research through licensing agreements and molecule outsourcing. The TTM revenue per share reflects the trend in unit profit, where the metric stands at 6.46. The company ensures the sustainability of its research through royalties, integrating strict environmental standards and bioethics into the production of immunological drugs.

Net income per share over 12 months measures the portion of total income attributable to a single security, allowing for an assessment of the actual efficiency of the business capitalization. The 12-month net income per share trend for AnaptysBio, Inc. (ANAB) reflects the stability of antibody licensing revenues, confirming the resilience of cash flows and the reliability of the company's investment profile.